[1]
|
Luo, Z., Li, L. and Ruan, B. (2012) Impact of the Implementation of a Vaccination Strategy on Hepatitis B Virus In-fections in China over a 20-Year Period. International Journal of Infectious Diseases, 16, E82-E88.
https://doi.org/10.1016/j.ijid.2011.10.009
|
[2]
|
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. https://doi.org/10.3969/j.issn.1001-5256.2019.12.007
|
[3]
|
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版) [J]. 中华传染病杂志, 2023, 41(1): 3-28. https://doi.org/10.3760/cma.j.cn311365-20230220-00050
|
[4]
|
Buti, M., Gane, E., Seto, W.K., et al. (2016) Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for the Treatment of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial. The Lancet Gas-troenterology & Hepatology, 1, 196-206.
https://doi.org/10.1016/S2468-1253(16)30107-8
|
[5]
|
Chan, H.L., Fung, S., Seto, W.K., et al. (2016) Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for the Treatment of HBeAg-Positive Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Infe- riority Trial. The Lancet Gastroenterology and Hepatology, 1, 185-195.
https://doi.org/10.1016/S2468-1253(16)30024-3
|
[6]
|
Kaneko, S., Kurosaki, M., Tamaki, N., et al. (2019) Tenofovir Alafenamide for Hepatitis B Virus Infection Including Switching Therapy from Tenofovir Disoproxil Fumarate. Journal of Gastroenterology and Hepatology, 34, 2004-2010.
https://doi.org/10.1111/jgh.14686
|
[7]
|
Lim, J., Choi, W.M., Shim, J.H., et al. (2022) Efficacy and Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in Treatment-Naïve Chronic Hepatitis B. Liver Interna-tional, 42, 1517-1527.
https://doi.org/10.1111/liv.15261
|
[8]
|
Jeong, S., Shin, H.P. and Kim, H.I. (2022) Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Intervirology, 65, 94-103. https://doi.org/10.1159/000519440
|
[9]
|
武媞, 黄康, 赵智蓉, 等. ALT升高、低病毒载量慢性乙型肝炎患者不确定期采用不同抗病毒治疗方案的疗效及安全性[J]. 昆明医科大学学报, 2023, 44(1): 97-103.
|
[10]
|
Byun, K.S., Choi, J., Kim, J.H., et al. (2022) Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching from Tenofovir Disoproxil Fumarate. Clinical Gastro-enterology and Hepatology, 20, 427-437.e5.
https://doi.org/10.1016/j.cgh.2021.04.045
|
[11]
|
Toyoda, H., Leong, J., Landis, C., et al. (2021) Treatment and Renal Outcomes up to 96 Weeks after Tenofovir Alafenamide Switch from Tenofovir Disoproxil Fumarate in Routine Practice. Hepatology, 74, 656-666.
https://doi.org/10.1002/hep.31793
|
[12]
|
Nguyen, M.H., Atsukawa, M., Ishikawa, T., et al. (2021) Outcomes of Sequential Therapy with Tenofovir Alafenamide after Long-Term Entecavir. American Journal of Gastroenterology, 116, 1264-1273.
https://doi.org/10.14309/ajg.0000000000001157
|
[13]
|
Ogawa, E., Nakamuta, M., Koyanagi, T., et al. (2022) Switching to Tenofovir Alafenamide for Nucleos(T)Ide Analogue-Experienced Patients with Chronic Hepatitis B: Week 144 Results from a Real-World, Multi-Centre Cohort Study. Alimentary Pharmacology & Therapeutics, 56, 713-722. https://doi.org/10.1111/apt.17107
|
[14]
|
Kumada, T., Toyoda, H., Tada, T., et al. (2021) Comparison of the Impact of Tenofovir Alafenamide and Entecavir on Declines of Hepatitis B Surface Antigen Levels. European Journal of Gastroenterology & Hepatology, 32, 255-260.
https://doi.org/10.1097/MEG.0000000000001733
|
[15]
|
Uchida, Y., Nakao, M., Tsuji, S., et al. (2020) Significance of Switching of the Nucleos(T)Ide Analog Used to Treat Japanese Patients with Chronic Hepatitis B Virus Infection from Entecavir to Tenofovir Alafenamide Fumarate. Journal of Medical Virology, 92, 329-338. https://doi.org/10.1002/jmv.25644
|
[16]
|
秦建增, 张玉华, 杜世奇. 慢性乙型肝炎实施富马酸丙酚替诺福韦治疗的效果与安全性分析[J]. 临床研究, 2021, 29(7): 85-87.
|
[17]
|
Wong, W.W.L., Pechivanoglou, P., Wong, J., et al. (2019) Antiviral Treatment for Treatment-Naïve Chronic Hepatitis B: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Systematic Reviews, 8, Article No. 207. https://doi.org/10.1186/s13643-019-1126-1
|
[18]
|
Wang, F.D., Zhou, J., Zhang, D.M., et al. (2022) A Study of the Effectiveness of Nucleos(T)Ide Analogues in the Treatment of HBeAg-Positive Chronic Hepatitis B with Normal Ala-nine Aminotransferase and High Level of HBV DNA. Chinese Journal of Hepatology, 30, 389-394.
|
[19]
|
程海林, 胡旭东, 夏冰, 等. 富马酸丙酚替诺福韦对恩替卡韦经治后低病毒载量的慢性乙型肝炎患者的临床疗效[J]. 临床肝胆病杂志, 2022, 38(3): 537-540. https://doi.org/10.3969/j.issn.1001-5256.2022.03.009
|
[20]
|
赵智蓉, 李海雯, 陆霓虹, 等.丙酚替诺福韦治疗慢性乙型肝炎的临床疗效[J]. 昆明医科大学学报, 2021, 42(1): 89-93. https://doi.org/10.12259/j.issn.2095-610X.S20210141
|
[21]
|
Chon, H.Y., Ahn, S.H., Kim, Y.J., et al. (2021) Effi-cacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Treatment-Naive Hepatitis B Patients. Hepatology International, 15, 1328-1336.
https://doi.org/10.1007/s12072-021-10262-y
|
[22]
|
Sripongpun, P., Kim, W.R., Mannalithara, A., et al. (2022) Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients with Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 20, 230-232. https://doi.org/10.1016/j.cgh.2020.11.047
|
[23]
|
Liang, L.Y., Yip, T.C., Lai, J.C., et al. (2022) Tenofovir Alafenamide Is Associated with Improved Alanine Aminotransferase and Renal Safety Compared to Tenofovir Disoproxil Fumarate. Journal of Medical Virology, 94, 4440- 4448. https://doi.org/10.1002/jmv.27863
|
[24]
|
Li, Z.B., Li, L., Niu, X.X., et al. (2021) Switching from Entecavir to Tenofovir Alafenamide for Chronic Hepatitis B Patients with Low-Level Viraemia. Liver International, 41, 1254-1264. https://doi.org/10.1111/liv.14786
|
[25]
|
Wong, G.L., Tse, Y.K., Wong, V.W., et al. (2015) Long-Term Safety of Oral Nucleos(T)Ide Analogs for Patients with Chronic Hepatitis B: A Cohort Study of 53,500 Subjects. Hepatology, 62, 684-693. https://doi.org/10.1002/hep.27894
|
[26]
|
Tien, C., Xu, J.J., Chan, L.S., et al. (2015) Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients Is Associated with Abnormal Renal Phosphate Handling. Digestive Diseases and Sciences, 60, 566-572.
https://doi.org/10.1007/s10620-014-3363-4
|
[27]
|
Kahraman, R., Şahin, A., Öztürk, O., et al. (2022) Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B. Turkish Journal of Gastroenterology, 33, 35-43.
https://doi.org/10.5152/tjg.2020.18024
|
[28]
|
Wong, G.L., Chan, H.L., Tse, Y.K., et al. (2018) Chronic Kidney Disease Progression in Patients with Chronic Hepatitis B on Tenofovir, Entecavir, or No Treatment. Alimentary Phar-macology & Therapeutics, 48, 984-992.
https://doi.org/10.1111/apt.14945
|
[29]
|
Scaglione, S.J. and Lok, A.S. (2012) Effectiveness of Hepatitis B Treatment in Clinical Practice. Gastroenterology, 142, 1360-1368.e1. https://doi.org/10.1053/j.gastro.2012.01.044
|
[30]
|
Scherzer, R., Estrella, M., Li, Y., et al. (2012) Association of Tenofovir Exposure with Kidney Disease Risk in HIV Infection. Aids, 26, 867-875. https://doi.org/10.1097/QAD.0b013e328351f68f
|
[31]
|
EASL (2017) 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398. https://doi.org/10.1016/j.jhep.2017.03.021
|
[32]
|
Jung, C.Y., Kim, H.W., Ahn, S.H., et al. (2022) Higher Risk of Kidney Function Decline with Entecavir than Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Liver In-ternational, 42, 1017-1026.
https://doi.org/10.1111/liv.15208
|
[33]
|
Farag, M.S., Fung, S., Tam, E., et al. (2021) Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. Journal of Viral Hepatitis, 28, 942-950.
https://doi.org/10.1111/jvh.13500
|
[34]
|
Hosaka, T., Suzuki, F., Kobayashi, M., et al. (2022) Renal Safety and Bi-ochemical Changes for 2 Years after Switching to Tenofovir Alafenamide from Long-Term Other Nucleotide Analog Treatment in Patients with Chronic Hepatitis B. Hepatology Research, 52, 153-164. https://doi.org/10.1111/hepr.13726
|
[35]
|
Fong, T.L., Lee, B.T., Tien, A., et al. (2019) Improvement of Bone Min-eral Density and Markers of Proximal Renal Tubular Function in Chronic Hepatitis B Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Journal of Viral Hepatitis, 26, 561-567. https://doi.org/10.1111/jvh.13053
|
[36]
|
Lee, B.T., Chang, M., Lim, C., et al. (2021) Bone and Renal Safety Profile at 72 Weeks after Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients. JGH Open: An Open Access Journal of Gastroenterology and Hepatology, 5, 258-263. https://doi.org/10.1002/jgh3.12481
|
[37]
|
Haskelberg, H., Hoy, J.F., Amin, J., et al. (2012) Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLOS ONE, 7, e38377.
https://doi.org/10.1371/journal.pone.0038377
|
[38]
|
Grigsby, I.F., Pham, L., Mansky, L.M., et al. (2010) Tenofovir Treatment of Primary Osteoblasts Alters Gene Expression Profiles: Implications for Bone Mineral Density Loss. Bio-chemical and Biophysical Research Communications, 394, 48-53. https://doi.org/10.1016/j.bbrc.2010.02.080
|
[39]
|
Seto, W.K., Asahina, Y., Brown, T.T., et al. (2018) Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate over 2 Years in Patients with Chronic HBV Infection. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2018.06.023
|
[40]
|
Que, X., Hung, M.Y., Yeang, C., et al. (2018) Oxidized Phospho-lipids Are Proinflammatory and Proatherogenic in Hypercholesterolaemic Mice. Nature, 558, 301-306. https://doi.org/10.1038/s41586-018-0198-8
|
[41]
|
Suzuki, K., Suda, G., Yamamoto, Y., et al. (2021) Tenofovir-Disoproxil-Fumarate Modulates Lipid Metabolism via Hepatic CD36/PPAR-Alpha Activation in Hepatitis B Virus Infection. Journal of Gastroenterology, 56, 168-180.
https://doi.org/10.1007/s00535-020-01750-3
|
[42]
|
Suzuki, K., Suda, G., Yamamoto, Y., et al. (2022) Effect of Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide on Lipid Profiles in Patients with Hepatitis B. PLOS ONE, 17, e0261760.
https://doi.org/10.1371/journal.pone.0261760
|
[43]
|
Jeong, J., Shin, J.W., Jung, S.W., et al. (2022) Tenofovir Alafenamide Treatment May Not Worsen the Lipid Profile of Chronic Hepatitis B Patients: A Propensity Score-Matched Analysis. Clinical and Molecular Hepatology, 28, 254-264.
https://doi.org/10.3350/cmh.2021.0314
|
[44]
|
Zhang, Y.Q., Li, Z.P., Luo, Q.M., et al. (2022) Changes in Blood Lipids in Patients with Chronic Hepatitis B after 48 Weeks of Tenofovir Alafenamide Treatment: A Prospective Re-al-World Clinical Study. Antiviral Therapy, 27.
https://doi.org/10.1177/13596535221082399
|
[45]
|
Yeh, M.L., Liang, P.C., Trinh, S., et al. (2022) Body Weight Changes in Treated Hepatitis B Patients Switching to Tenofovir Alafenamide. Journal of the Formosan Medical Asso-ciation, 121, 1273-1282.
https://doi.org/10.1016/j.jfma.2021.09.009
|
[46]
|
Hige, S., Aoki, K., Nakamoto, D., et al. (2024) Real-World Safety and Effectiveness of Tenofovir Alamenamide for 144 Weeks in Japanese Patients with Chronic Hepatitis B. Journal of Viral Hepatitis.
https://doi.org/10.1111/jvh.13912
|
[47]
|
Liu, Z., Zhao, Z., Ma, X., Liu, S. and Xin, Y. (2023) Renal and Bone Side Effects of Long-Term Use of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Patients with Hepatitis B: A Network Meta-Analysis. BMC Gastroenterology, 23, Article No. 384. https://doi.org/10.1186/s12876-023-03027-4
|
[48]
|
Ogawa, E., Jun, D.W., Toyoda, H., et al. (2024) Increased Spine Bone Density in Patients with Chronic Hepatitis B Switched to Tenofovir Alafenamide: A Prospective, Multinational Study. Alimentary Pharmacology & Therapeutics, 59, 239-248. https://doi.org/10.1111/apt.17785
|